COGT
Cogent Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$34.67
−0.80%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -28.6%
- EBIT
- -29.8%
- EPS
- +4.5%
- Free cash flow
- -31.8%
- Operating cash flow
- -31.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +12.7%
- EPS
- +15.7%
Three-year CAGR
- Revenue
- —
- EBITDA
- -27.7%
- EBIT
- -20.8%
- Net income
- -28.6%
- EPS
- +12.1%
- Free cash flow
- -27.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026